Spero Q2 net loss widens to $9.6M; FDA approves Utebzi, $105M financing extends runway

Spero Therapeutics, Inc.

2026-Q2 EPS reported -$0.29 revenue$258,000

Net loss of $9.6M ($0.16 diluted EPS) vs $1.7M loss ($0.03) in Q2 2025.
No revenue in Q2 2026 vs $14.2M in Q2 2025; all deferred revenue previously recognized.
Cash $50.8M at June 30, 2026; plus $105M royalty financing extends runway into H2 2029.
FDA approved Utebzi (tebipenem pivoxil) for cUTIs in June 2026; GSK launch expected by end of 2026.
Exclusive license with Innovent for SP001 (anti-CD40L) worldwide ex-Greater China; Phase 2 in IgG4-RD planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.